Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 24, 2013 - Issue 2
Submit an article Journal homepage
437
Views
6
CrossRef citations to date
0
Altmetric
Psoriasis

Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk

Edi KaminskaDepartment of Dermatology, University of Chicago, 5841 S. Maryland Avenue, MC 5067, Chicago, IL, USA
,
Isha Patel Clinical, Social and Administrative Sciences, College of Pharmacy, University of Michigan at Ann Arbor, 428 Church Street, Ann Arbor, MI, USA; Center for Medication Use, Policy, and Economics, The University of Michigan, 428 Church Street, Ann Arbor, MI, USA; Center of Global Health, The University of Michigan, 428 Church Street, Ann Arbor, MI, USACorrespondence[email protected]
,
Tushar S. DabadeDepartment of Dermatology, University of Chicago, 5841 S. Maryland Avenue, MC 5067, Chicago, IL, USA;Department of Dermatology, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, USA
,
Jongwha Chang Clinical, Social and Administrative Sciences, College of Pharmacy, University of Michigan at Ann Arbor, 428 Church Street, Ann Arbor, MI, USA; Center for Medication Use, Policy, and Economics, The University of Michigan, 428 Church Street, Ann Arbor, MI, USA; Center of Global Health, The University of Michigan, 428 Church Street, Ann Arbor, MI, USA
,
Ayub A. QureshiDepartment of Dermatology, University of Chicago, 5841 S. Maryland Avenue, MC 5067, Chicago, IL, USA;Department of Dermatology, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, USA
,
Jenna L O'NeillDepartment of Dermatology, University of Chicago, 5841 S. Maryland Avenue, MC 5067, Chicago, IL, USA;Department of Dermatology, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, USA
,
Rajesh Balkrishnan Clinical, Social and Administrative Sciences, College of Pharmacy, University of Michigan at Ann Arbor, 428 Church Street, Ann Arbor, MI, USA; Center for Medication Use, Policy, and Economics, The University of Michigan, 428 Church Street, Ann Arbor, MI, USA; Center of Global Health, The University of Michigan, 428 Church Street, Ann Arbor, MI, USA;Department of Health Management and Policy, The University of Michigan, 428 Church Street, Ann Arbor, MI, USA
&
Steven R. FeldmanDepartment of Dermatology, University of Chicago, 5841 S. Maryland Avenue, MC 5067, Chicago, IL, USA;Department of Dermatology, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, USA; Center for Worker Health, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, USA; Center for Integrative Medicine, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, USA;Department of Pathology, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, USA;Department of Social Sciences & Health Policy, Wake Forest University Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, USA
 show all
Pages 101-106 | Received 20 Dec 2010, Accepted 01 Jun 2011, Published online: 14 Jul 2011

References

  • Amgen and Wyeth Pharmaceuticals. Enbrel ® (etanercept) for subcutaneous injection [product information]. Available at: http://www.enbrel.com/pdf/enbrel_pi.pdf. 2008. Thousand Oaks, CA. (Accessed November 1 2010).
  • Centocor I. Remicade ® (infliximab) for IV injection [product information]. Available at: http://www.remicade.com/remicade/assets/HCP_PPI.pdf. 2008. Malvern, PA. (Accessed November 1 2010).
  • Abbott Laboratories. Humira ® (adalimumab) solution for subcutaneous injection [product information]. Available at: http://www.rxabbott.com/pdf/humira.pdf. 2008. North Chicago, IL. (Accessed November 1 2010).
  • Dharamsi JW, Bhosle M, Balkrishnan R, Yentzer BA, Feldman SR. Using “number needed to treat” to help conceptualize the magnitude of benefit and risk of TNFα inhibitors for patients with severe psoriasis. Br J Dermatol. 2009. [Epub ahead of print].
  • Behnam SM, Behnam SE, Koo JY. TNF-alpha inhibitors and congestive heart failure. Skinmed. 2005;4:363–368.
  • Calabresi PA. Chapter 436 – Multiple Sclerosis and Demyelinating Conditions of the Central Nervous System Goldman: Cecil Medicine, 23rd ed online. 2007 Saunders.
  • Lazoff M. Multiple Sclerosis, [updated March 2008]. Available at: http://emedicine.medscape.com/article/793013-overview, 2008. (Accessed April 1 2009).
  • Centers for Disease Control and Prevention (CDC). Trends in Tuberculosis – United States, 2008. MMWR Morb Mortal Wkly Rep. 2008;58:249–253.
  • Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89–92.
  • Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, Wolf PA. The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 2006;37:345–350.
  • Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD, Available at: http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009. (Accessed November 1 2010).
  • National Oceanic and Atmospheric Administration (NOAA), Available at: http://www.wrh.noaa.gov/ggw/newsletter/summer_05/LightningSafety.pdf, 2005. (Accessed November 1 2010).
  • National Safety Council, Odds of Death Due to Injury, United States, Available at: http://www.nsc.org/research/odds.aspx, 2005. (Accessed November 1 2010).
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, Available at: http://www.mrc-bsu.cam.ac.uk/cochrane/handbook500/chapter_9/9_2_2_1_risk_and_odds.htm, 2008. (Accessed November 1 2010).
  • Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004;22:S134–S140.
  • Keystone EC. Safety of biologic therapies, an update. J Rheumatol. 2005;32(Suppl):8–12.
  • Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148–155.
  • Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122–2127.
  • Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor alpha. California. 2002–2003. MMWR Morb Mortal Wkly Rep. 2004;53:683–686.
  • Symmons DP, Silman AJ. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum. 2004;50:1703–1706.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.